- Home
- NCNA
NCNA
NuCana plc
as 07-05-2024 4:00pm EST
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
| Founded: | N/A | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.8M | IPO Year: | 2017 |
| Target Price: | $125.00 | AVG Volume (30 days): | 13.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -16.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.53 - $21.52 | Next Earning Date: | 08-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NuCana plc News
NCNA Breaking Stock News: Dive into NCNA Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Top Premarket Decliners
GlobeNewswire
a month ago
NuCana to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
GlobeNewswire
2 months ago
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
3 months ago
NuCana Announces Completion of ADS Ratio Change
GlobeNewswire
3 months ago
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
GlobeNewswire
3 months ago
NuCana Announces Plan to Implement ADS Ratio Change
Share on Social Networks:
Disclaimer
The information presented on this page, "NCNA NuCana plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.